Author: Lei Lei; Hongbo Qian; Xiaofeng Yang; Xiaobo Zhou; Xingzhe Zhang; Dan Zhang; Tongxin Dai; Rui Guo; Lin Shi; Yanbin Cheng; Baojun Zhang; Jinsong Hu Hu; Yaling Guo
Title: The phenotypic changes of ?d T cells in COVID-19 patients Document date: 2020_4_7
ID: 5ekdfers_7
Snippet: Currently, there is no specific antiviral agent or vaccine available to treat SARS-CoV-2 infections. Clinical treatments for COVID-19 patients are primarily supportive and symptomatic treatments. Although there are several potential therapeutic targets to repurpose the existing antiviral agents or develop effective interventions against this novel coronavirus [6] , toxicology and clinical trials are required for potential uses in the clinic. Acco.....
Document: Currently, there is no specific antiviral agent or vaccine available to treat SARS-CoV-2 infections. Clinical treatments for COVID-19 patients are primarily supportive and symptomatic treatments. Although there are several potential therapeutic targets to repurpose the existing antiviral agents or develop effective interventions against this novel coronavirus [6] , toxicology and clinical trials are required for potential uses in the clinic. According to the pathological reports for COVID-19, it was shown that SARS-CoV-2 mainly caused inflammatory responses in the lungs [7] . Several studies showed that COVID-19 patients developed lymphopenia and rising pro-inflammatory cytokines in severe cases [8, 9] . Inflammation can be triggered when innate and adaptive immune cells detect SARS-CoV-2 infection. Innate T cells can provide a first line of defense against pathogens. However, how innate T cells respond to SARS-COV-2 infection remains unclear.
Search related documents:
Co phrase search for related documents- adaptive innate immune cell and inflammatory response: 1, 2, 3, 4, 5, 6, 7
- adaptive innate immune cell and novel coronavirus: 1
- adaptive innate immune cell and SARS infection: 1, 2, 3, 4, 5
- adaptive innate immune cell and therapeutic target: 1
- adaptive innate immune cell and unclear remain: 1
- antiviral agent and clinical treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antiviral agent and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- antiviral agent and defense line: 1, 2, 3, 4
- antiviral agent and immune cell: 1, 2, 3, 4, 5
- antiviral agent and inflammatory response: 1, 2, 3, 4, 5, 6, 7, 8
- antiviral agent and novel coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- antiviral agent and pathogens defense line: 1
- antiviral agent and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
- antiviral agent and SARS infection treat: 1
- antiviral agent and severe case: 1
- antiviral agent and specific antiviral agent: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- antiviral agent and therapeutic target: 1
- antiviral agent and unclear remain: 1
- antiviral agent and vaccine specific antiviral agent: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date